PH26376A - Heterocyclic bisphosphonic acid derivatives - Google Patents
Heterocyclic bisphosphonic acid derivatives Download PDFInfo
- Publication number
- PH26376A PH26376A PH39086A PH39086A PH26376A PH 26376 A PH26376 A PH 26376A PH 39086 A PH39086 A PH 39086A PH 39086 A PH39086 A PH 39086A PH 26376 A PH26376 A PH 26376A
- Authority
- PH
- Philippines
- Prior art keywords
- hydrogen atom
- lower alkyl
- general formula
- hydroxyl group
- alkyl group
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 21
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000005843 halogen group Chemical group 0.000 claims abstract description 9
- 125000004429 atom Chemical group 0.000 claims abstract description 8
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000002617 bone density conservation agent Substances 0.000 claims abstract description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- MXYOPVWZZKEAGX-UHFFFAOYSA-N 1-phosphonoethylphosphonic acid Chemical class OP(=O)(O)C(C)P(O)(O)=O MXYOPVWZZKEAGX-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 208000006386 Bone Resorption Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 230000024279 bone resorption Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- -1 pentyl(amyl) group Chemical group 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229940122361 Bisphosphonate Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108090000445 Parathyroid hormone Proteins 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000037147 Hypercalcaemia Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000004663 bisphosphonates Chemical class 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000000148 hypercalcaemia Effects 0.000 description 4
- 208000030915 hypercalcemia disease Diseases 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102100036893 Parathyroid hormone Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229910018830 PO3H Inorganic materials 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002723 inhibitory effect on hypercalcemia Effects 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OXOGLFBPOCMQCA-UHFFFAOYSA-N 2-[1-di(propan-2-yloxy)phosphorylethyl-propan-2-yloxyphosphoryl]oxypropane Chemical compound CC(C)OP(=O)(OC(C)C)C(C)P(=O)(OC(C)C)OC(C)C OXOGLFBPOCMQCA-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- WXEXZLQBGVKGFT-UHFFFAOYSA-N imidazo[1,2-a]pyridin-2-yl hydrogen carbonate;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(OC(=O)O)=CN21 WXEXZLQBGVKGFT-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20153588 | 1988-08-12 | ||
| JP20153688 | 1988-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26376A true PH26376A (en) | 1992-06-01 |
Family
ID=26512843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH39086A PH26376A (en) | 1988-08-12 | 1989-08-11 | Heterocyclic bisphosphonic acid derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4990503A (fr) |
| EP (1) | EP0354806B1 (fr) |
| KR (1) | KR0156239B1 (fr) |
| CN (1) | CN1027167C (fr) |
| AT (1) | ATE129714T1 (fr) |
| AU (1) | AU624405B2 (fr) |
| CA (1) | CA1332058C (fr) |
| DE (1) | DE68924681T2 (fr) |
| DK (1) | DK170257B1 (fr) |
| ES (1) | ES2082780T3 (fr) |
| GR (1) | GR3018086T3 (fr) |
| HU (2) | HU205766B (fr) |
| IE (1) | IE71185B1 (fr) |
| PH (1) | PH26376A (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0521622B1 (fr) * | 1991-07-03 | 1997-08-13 | PHARMACIA & UPJOHN COMPANY | Esters de l'acide pyrazolopyrimidine et pyrimidinyl bisphosphonique comme anti-inflammatoires |
| TW222637B (fr) * | 1991-12-12 | 1994-04-21 | Hoechst Ag | |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| JPH05345791A (ja) * | 1992-03-18 | 1993-12-27 | Hoechst Japan Ltd | 環状アミノメチレンビスホスホン酸誘導体 |
| AU4356693A (en) * | 1992-06-23 | 1994-01-24 | Yamanouchi Pharmaceutical Co., Ltd. | Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative |
| JPH08502287A (ja) * | 1992-10-09 | 1996-03-12 | ジ・アップジョン・カンパニー | 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび（アルコキシメチルホスフィニル）アルキルホスホン酸 |
| JPH06298779A (ja) * | 1993-04-15 | 1994-10-25 | Hoechst Japan Ltd | ヘテロ環イミノビスメチレンビスホスホン酸誘導体 |
| US5728650A (en) * | 1993-10-07 | 1998-03-17 | Zeneca Limited | Herbicidal aza bisphosphonic acids and compositions containing the same |
| US5854227A (en) * | 1994-03-04 | 1998-12-29 | Hartmann; John F. | Therapeutic derivatives of diphosphonates |
| US5880111A (en) * | 1995-06-07 | 1999-03-09 | Farcasiu; Dan | Therapeutic derivations of diphosphonates |
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| WO1998039342A1 (fr) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase |
| US7008645B2 (en) * | 1998-07-14 | 2006-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inhibiting restenosis using bisphosphonates |
| JP3219402B2 (ja) * | 1998-12-25 | 2001-10-15 | 山之内製薬株式会社 | 多発性骨髄腫の骨病変治療用医薬組成物 |
| US20030036537A1 (en) * | 2001-07-16 | 2003-02-20 | Marc Lecouvey | Bisphosphonate derivatives, their preparations and uses |
| NZ536273A (en) | 2002-12-20 | 2007-08-31 | Hoffmann La Roche | High dose ibandronate formulation |
| HUP0300227A2 (hu) * | 2003-01-28 | 2004-09-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására |
| US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
| US10517883B2 (en) * | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| CA2554749A1 (fr) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | Inhinbiteur recepteur p2x |
| CN101531681B (zh) * | 2008-03-10 | 2013-06-05 | 北京德众万全医药科技有限公司 | 一种高纯度的米诺膦酸及其制备方法 |
| WO2010033980A2 (fr) * | 2008-09-22 | 2010-03-25 | Isis Innovation Ltd. | 4-azaindole bisphosphonates |
| EP2350076B1 (fr) * | 2008-09-22 | 2013-08-21 | Isis Innovation Ltd | Imidazo[1,2- alpha]pyridinyle bisphosphonates |
| IN2012DN03448A (fr) | 2009-10-26 | 2015-10-23 | Warner Chilcott Co Llc | |
| CN101973993A (zh) * | 2010-11-05 | 2011-02-16 | 天津药物研究院 | 一种制备2-[咪唑并(1,2-a)吡啶-3-基]乙酸的方法 |
| CN102153585B (zh) * | 2011-02-24 | 2013-04-17 | 北京欧克兰医药技术开发中心 | 一种米诺膦酸中间体的合成方法及米诺膦酸的合成 |
| CN102268042B (zh) * | 2011-06-01 | 2014-06-25 | 广东宏远集团药业有限公司 | 一种米诺膦酸晶型ii及其制备方法 |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| CN107033187A (zh) * | 2017-04-28 | 2017-08-11 | 江苏笃诚医药科技股份有限公司 | 一种米诺膦酸的制备方法 |
| KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3203308A1 (de) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
| DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3626058A1 (de) * | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| IL84493A (en) * | 1986-11-21 | 1993-01-14 | Ciba Geigy Ag | Aromatically substituted azacycloalkylalk - anediphosphonic acids, their preparation and pharmaceutical compositions containing them |
| DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| EP0317505A1 (fr) * | 1987-11-13 | 1989-05-24 | Ciba-Geigy Ag | Acides azacycloalkylalcanediphosphoniques |
-
1989
- 1989-08-07 US US07/390,090 patent/US4990503A/en not_active Expired - Lifetime
- 1989-08-08 AU AU39419/89A patent/AU624405B2/en not_active Ceased
- 1989-08-09 CA CA000607874A patent/CA1332058C/fr not_active Expired - Fee Related
- 1989-08-11 PH PH39086A patent/PH26376A/en unknown
- 1989-08-11 ES ES89308180T patent/ES2082780T3/es not_active Expired - Lifetime
- 1989-08-11 DE DE68924681T patent/DE68924681T2/de not_active Expired - Fee Related
- 1989-08-11 AT AT89308180T patent/ATE129714T1/de not_active IP Right Cessation
- 1989-08-11 KR KR1019890011432A patent/KR0156239B1/ko not_active IP Right Cessation
- 1989-08-11 DK DK394789A patent/DK170257B1/da not_active IP Right Cessation
- 1989-08-11 IE IE260189A patent/IE71185B1/en not_active IP Right Cessation
- 1989-08-11 HU HU894150A patent/HU205766B/hu unknown
- 1989-08-11 EP EP89308180A patent/EP0354806B1/fr not_active Expired - Lifetime
- 1989-08-12 CN CN89106373A patent/CN1027167C/zh not_active Expired - Fee Related
-
1990
- 1990-08-10 US US07/566,145 patent/US5039669A/en not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00618P patent/HU211949A9/hu unknown
- 1995-11-15 GR GR950403204T patent/GR3018086T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US4990503A (en) | 1991-02-05 |
| AU3941989A (en) | 1990-02-15 |
| IE71185B1 (en) | 1997-01-29 |
| AU624405B2 (en) | 1992-06-11 |
| HU205766B (en) | 1992-06-29 |
| HU211949A9 (en) | 1996-01-29 |
| HUT51637A (en) | 1990-05-28 |
| ATE129714T1 (de) | 1995-11-15 |
| CA1332058C (fr) | 1994-09-20 |
| EP0354806B1 (fr) | 1995-11-02 |
| EP0354806A2 (fr) | 1990-02-14 |
| DK170257B1 (da) | 1995-07-17 |
| ES2082780T3 (es) | 1996-04-01 |
| DK394789A (da) | 1990-02-13 |
| CN1040590A (zh) | 1990-03-21 |
| DE68924681T2 (de) | 1996-04-04 |
| KR900003186A (ko) | 1990-03-26 |
| DE68924681D1 (de) | 1995-12-07 |
| CN1027167C (zh) | 1994-12-28 |
| GR3018086T3 (en) | 1996-02-29 |
| US5039669A (en) | 1991-08-13 |
| KR0156239B1 (ko) | 1998-12-01 |
| IE892601L (en) | 1990-02-12 |
| DK394789D0 (da) | 1989-08-11 |
| EP0354806A3 (fr) | 1991-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1332058C (fr) | Derives heterocycliques d'acide biphosphonique | |
| US5041428A (en) | (Cycloalkylamino)methylenebis(phosphonic acid) and medicines contaiing the same as an active ingredient | |
| CA1338895C (fr) | Derives de l'acide diphosphonique; methode de preparation et composition pharmaceutique a base de ces derives | |
| US6562974B2 (en) | Process for making geminal bisphosphonates | |
| US5013725A (en) | Pharmaceutical compositions substituted aminomethylenebis(phosphonic acid) derivatives | |
| EP0282320B1 (fr) | Dérivés d'acide bisphosphonique et médicaments les contenant | |
| CZ119893A3 (en) | Novel derivatives of methylene-bisphosphonic acid | |
| JPH0699457B2 (ja) | ヘテロ環ビスフォスフォン酸誘導体およびその医薬 | |
| EP0282309A2 (fr) | Dérivés de l'acide azole-aminométhylène-biphosphonique | |
| KR100246809B1 (ko) | 비고리형 아미딘기 함유 디포스폰산유도체, 이들의 제조방법 및 이들을 포함하는 의약조성물 | |
| JPH0248587A (ja) | 複素環置換ビスフォスフォン酸誘導体及びその医薬 | |
| JPH01258695A (ja) | （ピラゾリルアミノ）メチレンビス（ホスホン酸）誘導体及びその医薬 | |
| JPH06199880A (ja) | ヒドロキシホスフィニルホスホネートスクアレンシンセターゼインヒビターおよび方法 | |
| KR20010031269A (ko) | 신규한 메틸렌비스포스폰산 유도체 | |
| TW393488B (en) | Process for making 1-hydrox-ybisphosphonates | |
| JPH02288886A (ja) | 置換アミノメチレンビスフォスフォン酸誘導体 | |
| CA2186389A1 (fr) | Nouveaux derives de l'acide 2,4-diphosphonoglutarique, leur procede de fabrication et medicaments les renfermant |